Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496756 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00496756 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 14 participants.
The verdict
NCT00496756, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well sorafenib works in treating patients with metastatic or unresectable kidney cancer.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-03-01 |
| Est. Completion | 2014-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496756
The ClinicalTrials.gov registry entry for NCT00496756 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00496756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496756 about?
NCT00496756 is a clinical study titled "Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer". RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well sorafenib works in treating patients with metastatic or unresectable kidney ...
What is the current status of trial NCT00496756?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-03-01. Estimated completion is 2014-04-25.
What interventions are being tested in trial NCT00496756?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00496756?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.